Video

IDT Biologika Capacity Update October 2024: Cell & Gene Therapy

Source: IDT Biologika

With over 30 years of expertise in commercial filling and GMP manufacturing of vaccines and viral products, IDT Biologika is dedicated to advancing our clients' gene therapies.

We have established robust viral vector manufacturing capabilities and reserved capacity for filling both clinical and commercial batches. Our experienced team specializes in developing and producing viral vectors, particularly using Adeno-Associated Virus (AAV) platforms, and offers proprietary cell lines to support efficient and reliable manufacturing processes.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Discovery Online

Please tell us more about you so that we can customize our newsletters to your specific interests:

IDT Biologika